DOD Military Burn - Idea Development Award | W81XWH 19 MBRP IDA

Opportunity Information: Apply for W81XWH 19 MBRP IDA

The DOD Military Burn - Idea Development Award (MBRP IDA) is a Department of Defense funding opportunity run through the Congressionally Directed Medical Research Programs (CDMRP) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). Introduced for the first time in FY19, this award is designed to back highly impactful, military-relevant work focused specifically on burn wound care. The program is aimed at practical progress, meaning it supports applied research and preclinical research rather than early, curiosity-driven science. Projects are expected to address real-world challenges faced by Service members and Veterans, with results that can also translate to broader civilian benefit.

A central driver behind the opportunity is the reality that burns have consistently made up a meaningful share of combat casualties across modern conflicts (roughly 5 to 20 percent, as cited in the announcement). The DoD is planning for future scenarios where burn injuries could increase, especially in austere or rural combat environments and mass-casualty situations where evacuation and definitive care may be delayed. Because of that, the call emphasizes solutions that can be used closer to the point of injury, including pre-hospital care and settings where medical teams may have to manage patients for extended periods with limited resources.

The announcement highlights prolonged field care (PFC) as a major operational need. NATO defines PFC as trauma care that extends beyond normal doctrinal timelines until evacuation to a higher level of care becomes possible. The program notes that PFC is considered a capability gap across the Army and other military services. While applicants are encouraged to align proposals with prolonged field care realities, addressing PFC is not strictly required. What is required is clear relevance to active duty personnel and/or Veterans, along with a credible pathway to outcomes that matter in military medicine.

Competitiveness expectations are spelled out clearly. Applicants must include preliminary and/or published data that directly supports the proposed work. The application should present a strong scientific rationale, logical reasoning, and a well-formed, testable hypothesis. In other words, the program is not looking for purely speculative ideas; it is looking for concepts that are already grounded in evidence and ready to be developed into something usable through applied or preclinical investigation.

Funding is capped at a total cost budget of up to $500,000 for the full period of performance per award. The DoD anticipated allocating about $2 million from FY19 funds to support around four awards, with the possibility of up to another $2 million from FY20 funds to support up to four additional awards if funding was appropriated. Altogether, the notice projected up to eight awards. As with most federal programs, actual awards depend on available appropriations, the number of submissions, and how applications score in both scientific peer review and programmatic review. The timeline in the announcement indicates that awards were expected to be made no later than September 30, 2021, and it explains that FY19 and FY20 funds carried obligation deadlines tied to those fiscal years.

Awards under this opportunity are issued as assistance agreements, meaning either grants or cooperative agreements. The difference is based on how involved the DoD expects to be during the project. If substantial DoD involvement is anticipated (such as collaboration, participation, or intervention in the work), the award may be a cooperative agreement; if not, it is more likely to be a standard grant. The final instrument type and start date are typically settled during award negotiations.

There are important scope restrictions. The IDA cannot be used to support fundamental basic research, which the announcement defines as work intended mainly to increase knowledge of underlying phenomena without a specific application in mind. Clinical trials are explicitly not allowed under this mechanism, using a definition that includes prospective assignment of human subjects to interventions to measure biomedical or behavioral outcomes. Applicants interested in clinical research are directed instead to the program's Clinical Translational Research Award mechanism.

The opportunity also lays out compliance requirements for studies involving animals or human-derived materials. Any animal research funded by DoD must be reviewed not only by the institution's IACUC but also by the USAMRMC Office of Research Protections Animal Care and Use Review Office (ACURO). IACUC approval is not required at the time of application submission, but ACURO approval is required before work begins, and investigators are warned to plan for roughly two to three months for that regulatory review. Similarly, research involving human anatomical substances, human subjects, or human cadavers requires review by the USAMRMC Human Research Protection Office (HRPO) in addition to local IRB or ethics review. Local approval is not required at submission, but HRPO review is mandatory before implementation, and investigators are advised to plan for at least two to three months (potentially longer for international work). The announcement also cautions that protocols should ideally be written as stand-alone efforts specific to the DoD-supported scope, because HRPO may require review of the entire protocol if it includes broader non-DoD work, which can complicate timelines and compliance.

If a project depends on access to DoD or VA patient populations, databases, or other resources, the application must describe how that access will be obtained and maintained. The program expects documentation such as letters of support signed by an appropriate approving authority. For VA-related access, letters typically need to come from the VA Facility Director or a delegated official (for example, the Associate Chief of Staff for Research and Development). The announcement notes that certain DoD and VA resources may be restricted, meaning outside investigators may need a substantive collaboration with a DoD or VA investigator to gain access. If access is not adequately documented, the government reserves the right to delay, withdraw, or revoke funding until access is demonstrated.

Finally, the program strongly encourages collaboration and alignment with DoD and/or VA laboratories and research programs, emphasizing that military relevance is a defining feature of the award. The announcement provides a long list of potential defense and veterans research organizations as starting points for identifying partners or aligning with existing efforts. Eligibility is described as unrestricted (open to many entity types) unless otherwise clarified in the full opportunity details, and the opportunity was listed under CFDA 12.420 with a funding opportunity number W81XWH-19-MBRP-IDA.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Military Burn - Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 01, 2019.
• Applicants must submit their applications by Jul 10, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 MBRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: